Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Proteostasis Therapeutics, Inc., and Announces Conference-Call Schedule

Tuesday, March 20, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

- Kerrisdale believes that Proteostasis Therapeutics' investigational cystic-fibrosis drug, PTI-428, is ineffective and will fail future Phase 3 trials

NEW YORK, March 20, 2018 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a negative report

explaining its short position in Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a development-stage biopharmaceutical company whose market value is based primarily on PTI-428, its lead drug candidate for the treatment of cystic fibrosis. Proteostasis's stock price increased ~100% after the FDA granted the drug Breakthrough Therapy and Orphan Drug designations, but Kerrisdale's analysis demonstrates that PTI-428 is likely ineffective. Kerrisdale also details a pattern of low-quality data and troubling omissions in Proteostasis's public disclosures.

The full report can be found at http://kerr.co/pti.

Kerrisdale has a short position in Proteostasis Therapeutics, Inc., and stands to benefit if its share price falls.

Conference Call ScheduleKerrisdale will host a conference call on Tuesday, March 20 at 10:30am ET to discuss the Proteostasis report.

To participate in the conference call, dial (866) 834-3313 (United States) or (409) 981-0700 (international) and reference the Kerrisdale Capital call.

About Kerrisdale CapitalKerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.

ContactAgnes CaoKerrisdale Capital acao@kerrisdalecap.com 212-257-4385

Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.

Cision View original content:http://www.prnewswire.com/news-releases/sahm-adrangis-kerrisdale-capital-issues-negative-report-on-proteostasis-therapeutics-inc-and-announces-conference-call-schedule-300616553.html

SOURCE Kerrisdale Capital Management, LLC

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store